173 related articles for article (PubMed ID: 23270334)
21. Barrett's oesophagus: microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence.
Gleeson CM; Sloan JM; McGuigan JA; Ritchie AJ; Weber JL; Russell SE
Genes Chromosomes Cancer; 1998 Jan; 21(1):49-60. PubMed ID: 9443041
[TBL] [Abstract][Full Text] [Related]
22. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
23. Malignant progression in Barrett's esophagus: pathology and molecular biology.
Mueller J; Werner M; Siewert JR
Recent Results Cancer Res; 2000; 155():29-41. PubMed ID: 10693236
[TBL] [Abstract][Full Text] [Related]
24. Clinical use of p53 in Barrett's esophagus.
Keswani RN; Noffsinger A; Waxman I; Bissonnette M
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1243-9. PubMed ID: 16835318
[TBL] [Abstract][Full Text] [Related]
25. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases.
Schneider PM; Casson AG; Levin B; Garewal HS; Hoelscher AH; Becker K; Dittler HJ; Cleary KR; Troster M; Siewert JR; Roth JA
J Thorac Cardiovasc Surg; 1996 Feb; 111(2):323-31; discussion 331-3. PubMed ID: 8583805
[TBL] [Abstract][Full Text] [Related]
26. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia.
Neshat K; Sanchez CA; Galipeau PC; Blount PL; Levine DS; Joslyn G; Reid BJ
Gastroenterology; 1994 Jun; 106(6):1589-95. PubMed ID: 8194706
[TBL] [Abstract][Full Text] [Related]
27. p53 protein overexpression and p53 mutation analysis in patients with intestinal metaplasia of the cardia and Barrett's esophagus.
Segal F; Kaspary AP; Prolla JC; Leistner S
Cancer Lett; 2004 Jul; 210(2):213-8. PubMed ID: 15183537
[TBL] [Abstract][Full Text] [Related]
28. Validation of a biomarker panel in Barrett's esophagus to predict progression to esophageal adenocarcinoma.
Eluri S; Klaver E; Duits LC; Jackson SA; Bergman JJ; Shaheen NJ
Dis Esophagus; 2018 Nov; 31(11):. PubMed ID: 29635420
[TBL] [Abstract][Full Text] [Related]
29. Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma.
Zhuang Z; Vortmeyer AO; Mark EJ; Odze R; Emmert-Buck MR; Merino MJ; Moon H; Liotta LA; Duray PH
Cancer Res; 1996 May; 56(9):1961-4. PubMed ID: 8616831
[TBL] [Abstract][Full Text] [Related]
30. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.
Lomo LC; Blount PL; Sanchez CA; Li X; Galipeau PC; Cowan DS; Ayub K; Rabinovitch PS; Reid BJ; Odze RD
Am J Surg Pathol; 2006 Apr; 30(4):423-35. PubMed ID: 16625087
[TBL] [Abstract][Full Text] [Related]
31. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
32. Polypoid dysplasia in Barrett's esophagus: a clinicopathologic, immunohistochemical, and molecular study of five cases.
Thurberg BL; Duray PH; Odze RD
Hum Pathol; 1999 Jul; 30(7):745-52. PubMed ID: 10414492
[TBL] [Abstract][Full Text] [Related]
33. Loss of heterozygosity at thymidylate synthase locus in Barrett's metaplasia, dysplasia, and carcinoma sequences.
Kuramochi H; Uchida K; Peters JH; Shimizu D; Vallbohmer D; Schneider S; Danenberg KD; Danenberg PV
BMC Cancer; 2009 May; 9():157. PubMed ID: 19460136
[TBL] [Abstract][Full Text] [Related]
34. 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia.
Sanz-Ortega J; Hernández S; Saez MC; Sierra E; Sanz-Ortega G; Torres A; Balibrea JL; Sanz-Esponera J; Merino MJ
Hepatogastroenterology; 2003; 50(50):404-7. PubMed ID: 12749233
[TBL] [Abstract][Full Text] [Related]
35. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
Galipeau PC; Li X; Blount PL; Maley CC; Sanchez CA; Odze RD; Ayub K; Rabinovitch PS; Vaughan TL; Reid BJ
PLoS Med; 2007 Feb; 4(2):e67. PubMed ID: 17326708
[TBL] [Abstract][Full Text] [Related]
36. Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma.
Kaz AM; Grady WM; Stachler MD; Bass AJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):473-89. PubMed ID: 26021206
[TBL] [Abstract][Full Text] [Related]
37. [Morphology and biology of invasion with Barret's carcinoma as an example].
Werner M; Walch A
Verh Dtsch Ges Pathol; 2000; 84():62-8. PubMed ID: 11217450
[TBL] [Abstract][Full Text] [Related]
38. [The molecular genetic alterations in mucosa of intestines as markers of oncologic progression and estimate of effectiveness of anti-reflux operations in patients with Barrett's esophagus].
Osminin SV; Vetshev FP; Rudenko VV; Zaletaev DV; Khorobrykh TV; Nemtsova MV
Klin Lab Diagn; 2016 Oct; 61(10):681-5. PubMed ID: 30615323
[TBL] [Abstract][Full Text] [Related]
39. Changes in mitochondrial stability during the progression of the Barrett's esophagus disease sequence.
O'Farrell NJ; Feighery R; Picardo SL; Lynam-Lennon N; Biniecka M; McGarrigle SA; Phelan JJ; MacCarthy F; O'Toole D; Fox EJ; Ravi N; Reynolds JV; O'Sullivan J
BMC Cancer; 2016 Jul; 16():497. PubMed ID: 27431913
[TBL] [Abstract][Full Text] [Related]
40. Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus.
Grady WM; Yu M
Dig Dis Sci; 2018 Aug; 63(8):2059-2069. PubMed ID: 29766388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
